Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1244 participants.
Also called NCT07116928
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,244 participants
- Registry
-
NCT07116928
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07116928. Randomized; quadruple masking; primary purpose treatment. Start 2025-11-30 (anticipated); primary completion 2031-10-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
- Acronym
- GLOW-CKD
- Condition
- T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug)
- ganagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07116928- Content hash
6846cbe440dac403dcc508c02b0653cf729ef93c90a5202d01b9437e28640c16